What insulin sliding‑scale protocol should be used for a hospitalized 70‑kg adult with normal renal function and type 2 diabetes or stress‑related hyperglycemia, including rapid‑acting insulin dosing based on glucose ranges, monitoring frequency, and dose adjustments?

Insulin Sliding Scale Protocol for Hospitalized Adults

For a hospitalized 70-kg adult with normal renal function and type 2 diabetes or stress-related hyperglycemia, start with correctional (sliding scale) insulin alone only if admission glucose is <180 mg/dL; if glucose is ≥180 mg/dL or if two glucose readings reach ≥180 mg/dL within 24 hours on correctional insulin alone, immediately transition to scheduled basal-bolus insulin therapy. 1

Initial Approach Based on Admission Glucose

For Admission Glucose <180 mg/dL

• Start with correctional insulin alone using rapid-acting insulin (lispro, aspart, or glulisine) 1
• Target glucose range: 100-180 mg/dL 1
• Monitor glucose every 4-6 hours (before meals and bedtime if eating; every 4 hours if NPO) 2

For Admission Glucose ≥180 mg/dL

• Skip sliding scale entirely and initiate scheduled basal-bolus insulin immediately 1
• This prevents the ineffective reactive approach of sliding scale alone

Correctional Insulin Dosing (When Appropriate)

For a 70-kg patient, use the following rapid-acting insulin correction doses based on glucose ranges:

Standard Sensitivity Scale:

• 141-180 mg/dL: 2 units
• 181-220 mg/dL: 4 units
• 221-260 mg/dL: 6 units
• 261-300 mg/dL: 8 units
• 301-350 mg/dL: 10 units

• 350 mg/dL: 12 units and notify physician

Important caveat: Recent evidence suggests bedtime sliding scale insulin is unnecessary for glucose <300 mg/dL, as it may cause morning hypoglycemia without improving control 3

When to Transition to Scheduled Insulin

Mandatory transition criteria (abandon sliding scale alone):

• ≥2 glucose readings ≥180 mg/dL within any 24-hour period 1
• Persistent hyperglycemia despite correctional insulin
• Patient already on insulin therapy prior to admission 1

Scheduled Basal-Bolus Insulin Protocol

Calculate Total Daily Dose (TDD)

• For insulin-naive patients: 0.3-0.5 units/kg/day 4, 5
• For a 70-kg patient: Start with 21-35 units/day (use 0.3 units/kg = 21 units for conservative approach)

Divide the TDD:

• 50% as basal insulin (long-acting: glargine, detemir, or degludec)
  • For 70-kg patient: 10-11 units once daily
• 50% as prandial insulin (rapid-acting: divided over 3 meals)
  • For 70-kg patient: 3-4 units before each meal
• Add correctional insulin on top of prandial doses using the scale above 4, 5

Key Distinction from Traditional Sliding Scale

The correctional component here is a fine-tuning adjustment added to scheduled doses, not the sole therapy. This physiologic approach has demonstrated reduced hyperglycemia, less hypoglycemia, and shorter hospital stays compared to sliding scale alone 4

Monitoring Frequency

• Point-of-care glucose testing:
  • Before each meal and bedtime (if eating) 2
  • Every 4 hours if NPO 2
  • Every 2-4 hours if critically ill or on IV insulin 2

Dose Adjustments

If glucose remains >180 mg/dL:

• Increase TDD by 10-20% 5
• Adjust the specific insulin component (basal vs prandial) based on timing of hyperglycemia

If hypoglycemia occurs (<70 mg/dL):

• Reduce TDD by 10-20% 5
• Consider reducing basal insulin if fasting hypoglycemia
• Consider reducing prandial insulin if postprandial hypoglycemia

Critical Pitfalls to Avoid

1. Do not use sliding scale insulin alone for patients with admission glucose ≥180 mg/dL - this is reactive, not proactive, and leads to poor control 1, 6

2. Do not give bedtime rapid-acting insulin for glucose <300 mg/dL - this increases morning hypoglycemia without benefit 3

3. Do not continue sliding scale alone if two readings reach ≥180 mg/dL - this signals inadequate therapy requiring scheduled insulin 1

4. For patients on insulin prior to admission: Continue their scheduled regimen (modified for illness severity), do not revert to sliding scale alone 1

5. Avoid overly aggressive correction at bedtime - the risk of nocturnal hypoglycemia outweighs marginal glucose improvement 3

Evidence Quality and Guideline Strength

The Endocrine Society 2022 guidelines 1 provide the strongest framework, explicitly recommending against sliding scale monotherapy for most hospitalized patients. The ADA 2025 guidelines 2 support glucose targets of 100-180 mg/dL and emphasize scheduled insulin for surgical patients. Research consistently shows sliding scale alone is ineffective after 40+ years of use 4, 6, 7, with very low-certainty evidence supporting its use 6.

The evidence strongly favors abandoning traditional sliding scale insulin as monotherapy in favor of physiologic basal-bolus regimens with correctional insulin as an adjunct.